Explore

Rapid Read Rapid Read
Columbia University Researchers Develop New Breast Cancer Test Using Topology for Improved Survival Predictions

Columbia University Researchers Develop New Breast Cancer Test Using Topology for Improved Survival Predictions

Researchers at Columbia University have developed a novel approach to diagnosing and grading breast cancer by utilizing mathematical tools known as topology. This method transforms visual patterns into quantitative measurements, potentially enhancing the accuracy of predicting breast cancer outcomes and informing treatment decisions. Traditional methods involve examining tissue samples under a microscope to assess changes in tissue and cell structure. The new topology-based biomarkers provide numerical scores that predict patient survival and treatment response more accurately than conventional biomarkers, with less variation across racial and ethnic groups. Dr. Kevin Gardner, a pathologist at Columbia University, emphasized the integration of digital pathology, AI, and machine learning in this research to create a comprehensive understanding of individual cancers. The study involved analyzing tumor samples from over 550 breast cancer patients, revealing that topology-based measurements strongly correlate ...
Rapid Read Rapid Read
New Breast Cancer Test Enhances Survival Prediction and Treatment

New Breast Cancer Test Enhances Survival Prediction and Treatment

Researchers at Columbia University have developed a new method for diagnosing and grading breast cancer that could significantly impact treatment and survival rates. This approach involves transforming visual patterns of tumor tissues into quantitative measurements using mathematical tools known as topology. The new method provides numerical scores that predict patient survival and treatment response more accurately than traditional biomarkers. This advancement could lead to more personalized treatment decisions by offering a more complete picture of an individual's cancer. The study involved mapping the spatial organization of tumor and immune cells in samples from over 550 breast cancer patients, revealing that topology-based measurements strongly predict survival outcomes.
Rapid Read Rapid Read
Ultrasound Technology Advances with Lipid-Shelled Nanobubbles for Enhanced Imaging

Ultrasound Technology Advances with Lipid-Shelled Nanobubbles for Enhanced Imaging

Recent developments in ultrasound technology have introduced lipid-shelled nanobubbles as a promising contrast agent for medical imaging. These nanobubbles are designed to improve the sensitivity and specificity of ultrasound imaging, particularly in detecting diseases involving pathological vasculature. Unlike traditional microbubbles, which are larger, nanobubbles offer a smaller size that can be more broadly applicable across various medical fields. They have been utilized in preclinical applications, including oncology and endocrinology, to enhance both diagnostic and therapeutic outcomes. The lipid shell composition of these nanobubbles allows for better interaction with ultrasound waves, potentially leading to more precise imaging results.
Trendline Trendline
Flatiron Health Partners with NHSGGC to Expand Global Oncology Network

Flatiron Health Partners with NHSGGC to Expand Global Oncology Network

Flatiron Health Partners with NHSGGC to Expand Global Oncology Network
Rapid Read Rapid Read
RNA-Based Testing Enhances Detection of Lung Cancer Biomarkers, Improving Diagnostic Accuracy

RNA-Based Testing Enhances Detection of Lung Cancer Biomarkers, Improving Diagnostic Accuracy

Recent research published in The Journal of Molecular Diagnostics highlights the advantages of RNA-based testing over DNA-only approaches in detecting MET exon 14 skipping in lung cancer patients. This study, conducted by researchers at the University of Cologne, found that RNA analysis could identify a broader spectrum of genomic alterations, which are often missed by DNA-based tests. The study involved a large cohort of non-small cell lung cancer (NSCLC) patients and demonstrated that RNA-based testing could improve the sensitivity and specificity of diagnostic assays. The findings suggest that incorporating RNA-based confirmation in diagnostic workflows could enhance the accuracy of identifying patients eligible for MET-targeted therapies.
Rapid Read Rapid Read
Summit 2.0 Test Influences Clinical Decisions in CNS Cancer Cases

Summit 2.0 Test Influences Clinical Decisions in CNS Cancer Cases

Belay Diagnostics has announced that its Summit 2.0 cerebrospinal fluid liquid biopsy test has significantly influenced clinical decision-making in 86% of cases involving central nervous system (CNS) malignancies. The study, co-authored with Johns Hopkins University School of Medicine, surveyed 22 clinicians across 17 institutions. The test was found to aid in diagnosis, treatment selection, and prognosis, even when no genetic variants were detected. The Summit 2.0 test provides a non-invasive alternative to traditional tissue biopsies, offering valuable molecular insights from a standard lumbar puncture.
Rapid Read Rapid Read
Proteomics Advances in Personalized Medicine Highlighted by Jennifer Van Eyk

Proteomics Advances in Personalized Medicine Highlighted by Jennifer Van Eyk

Jennifer Van Eyk, a prominent figure in the field of proteomics, emphasizes the critical role of proteomics in advancing personalized medicine. Her work focuses on developing scalable proteomic pipelines for therapeutic screening, aiming to identify new drugs and targeted treatments. Van Eyk highlights the limitations of a genomics-first approach and stresses the importance of proteomics in understanding disease mechanisms and therapy responses. Despite technological advancements, financial models and regulatory hurdles remain significant barriers to the clinical adoption of biomarkers. Van Eyk's research underscores the potential of proteomics to drive precision medicine forward, particularly in areas like cancer prediction and treatment.
Trendline Trendline
Amprion Secures Funding to Enhance Neurodegenerative Disease Testing

Amprion Secures Funding to Enhance Neurodegenerative Disease Testing

Amprion Secures Funding to Enhance Neurodegenerative Disease Testing
Rapid Read Rapid Read
AI Tool Enhances Monitoring of Myelodysplastic Neoplasms

AI Tool Enhances Monitoring of Myelodysplastic Neoplasms

Researchers at Weill Cornell Medicine have developed an AI-based method to improve the monitoring of myelodysplastic neoplasms (MDS), a form of blood cancer. The new tool, called the MDS-Microarchitectural Perturbation Score (MDS-MAPS), analyzes bone marrow samples to assess disease severity. By comparing the physical and morphometric characteristics of hematopoietic cells in patient samples with those in healthy bone marrow, the AI generates a score indicating disease progression. This method aims to provide more precise diagnoses and track changes over time, potentially improving patient outcomes.
Trendline Trendline
Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder
Rapid Read Rapid Read
Neurotransmitter Modulation Offers New Pathways in Cancer Treatment

Neurotransmitter Modulation Offers New Pathways in Cancer Treatment

A recent study has highlighted the role of neurotransmitters in modulating the tumor microenvironment (TME) in triple-negative breast cancer (TNBC). Researchers found that calcitonin gene-related peptide (CGRP), secreted by tumor-innervating sensory neurons, significantly alters the TME, affecting immune cell infiltration and fibrosis. The study demonstrated that targeting the receptor RAMP1, which binds CGRP, can reduce fibrosis and enhance immune infiltration, improving the efficacy of immune checkpoint inhibitors. This research underscores the importance of considering neuronal influences in cancer treatment strategies.
Rapid Read Rapid Read
Weill Cornell Medicine Develops AI Method for Blood Cancer Prognosis

Weill Cornell Medicine Develops AI Method for Blood Cancer Prognosis

Researchers at Weill Cornell Medicine have introduced a new AI-based method to assess patients with myelodysplastic neoplasms (MDS), a form of blood cancer. This method, detailed in a study published in Leukemia, evaluates the spatial architecture of bone marrow to generate a score reflecting disease severity. The MDS-Microarchitectural Perturbation Score (MDS-MAPS) ranks patient samples based on 82 features associated with normal tissue and various genetic subtypes of MDS. This tool utilizes routinely collected samples and imaging technologies, potentially implementable in most hospital pathology departments. The study aims to provide more clarity for MDS patients and their physicians, improving prognosis assessments and potentially guiding precision therapies.